![]() |
|
|
Vol. 27, Issue 11, 1254-1259, November 1999
)-Gallopamil:
Utility of In Vitro Disappearance Rate
Pharmaceutical Research Laboratories, Taisho Pharmaceutical Co.,
Ltd. (A.S., I.I., F.T., M.A., K.F.), Saitama; Department of Clinical
Pharmacology, Isoforms of cytochrome P-450 (CYP) involved in the
metabolism of gallopamil enantiomers were identified by measuring the
disappearance rate of parent drug from an incubation mixture with human
liver microsomes and recombinant human CYPs. Mean (± S.D.) intrinsic clearances (CLint) of R(+)- and
S(
)-gallopamil in human liver microsomes were
0.320 ± 0.165 and 0.205 ± 0.107 ml/min/mg protein, respectively. These values were highly correlated with the
6
-hydroxylation activity of testosterone, a marker substrate of
CYP3A4 (r = 0.977 and 0.900 for
R(+)- and S(
)-gallopamil, respectively,
p < .001). Ketoconazole and troleandomycin,
selective inhibitors of CYP3A4, and polyclonal antibodies raised
against CYP3A4/5 markedly reduced the CLint of gallopamil
enantiomers in human liver microsomes. Among the 10 recombinant human
CYP isoforms, CYP3A4 exhibited the highest CLint of
gallopamil enantiomers, and CYP2C8 and CYP2D6 also exhibited
appreciable activity. When the contribution of CYP3A4 to the total
metabolic clearance of gallopamil enantiomers in human liver microsomes
was estimated by relative activity factor, the mean (± S.D.)
contributions were 92 ± 18 and 68 ± 19% for R(+)- and S(
)-gallopamil, respectively.
These values were comparable to the rates of immunoinhibition by
antibodies raised against CYP3A4/5 observed in human liver microsomes.
The present study suggests that CYP3A4 is a major isoform involved in
the overall metabolic clearance of gallopamil enantiomers in the human
liver, and that the present approach based on disappearance rate may be
applicable to identify major isoforms of CYP involved in the metabolism
of a drug in human liver microsomes.
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Jones and J. B. Houston SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS Drug Metab. Dispos., September 1, 2004; 32(9): 973 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kobayashi, N. Mimura, H. Fujii, H. Minami, Y. Sasaki, N. Shimada, and K. Chiba Role of Human Cytochrome P450 3A4 in Metabolism of Medroxyprogesterone Acetate Clin. Cancer Res., August 1, 2000; 6(8): 3297 - 3303. [Abstract] [Full Text] |
||||